National Breast Cancer Foundation and Love Your Sister Announce New Co-Funded Research Grants

Despite uncertain times, the National Breast Cancer Foundation (NBCF) and Love Your Sister (LYS) are together committed to funding research grants in the coming year through jointly co-funding the IIRS grants scheme in the coming year.

The scheme this year will support vital research that specifically addresses precision medicine. Precision medicine aims to accurately predict and individually tailor which breast cancer prevention and treatment strategies work most effectively for different patients.

NBCF and LYS believe that the grants being focused on a precision approach to prevention and medical treatment this year will improve diagnostic and screening programs through new technologies, enabling greater preventative options and targeted medical treatments which will ultimately, help stop deaths from breast cancer.

“This year, nearly 20,000 Australians will be diagnosed with breast cancer.  Unfortunately, more than 3,000 women and men will lose their lives to this disease. The joint funding initiative from NBCF and LYS in precision medicine will give researchers the opportunity to find the best individualised treatment and preventative options as we work towards our goal of Zero Deaths from breast cancer,” says Professor Sarah Hosking, CEO of NBCF.

Samuel Johnson from LYS added: “Our priority is to fund precision medicine because treating cancer isn’t a one-size fits all approach. We need to fund research that ensures each person gets the treatment best suited to them and I’m thrilled that LYS’ continued collaboration with NBCF will see further great research in this area being funded.”

In total, NBCF has funded over $181 million into 557 world-class breast cancer research projects since its inception in 1994. To date, LYS has funded five breast cancer research projects through NBCF’s IIRS funding scheme from 2019 – 2020.

NBCF and LYS’ funding partnership this year ensures that much-needed breast cancer research is funded in order to improve outcomes for breast cancer patients who continue to be affected during unprecedented times such as these.